The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with parenchymal ICH or non-ICH major hemorrhage
Timeframe: Up to 12 months
Number of participants with ischemic stroke, intracerebral hemorrhage or vascular death
Timeframe: Up to 12 months